Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

Nuclear PARP1‐Targeted Photosensitizer as a Dual‐Mode DNA‐Damaging Agent and Immune Activator for Tumor Ablation (Adv. Healthcare Mater. 31/2023)

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy

Programming DNA Nanoassembly for Enhanced Photodynamic Therapy

PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy.

Breaking the Iron Homeostasis: A “trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition

A Molecular‐Targeting Photosensitizer to Inhibit DNA Damage Repair System and Induce cGAS‐STING Pathway Activation for Photo‐Immunotherapy of Ovarian Cancer

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

Molecular Pathways: Targeting PARP in Cancer Treatment

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer

Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities

The discovery of a potent PARP1 inhibitor Senaparib

Discovery of a potent PARP1 PROTAC as a chemosensitizer for the treatment of colorectal cancer

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

Synthesis and biological evaluation of a tumor-selective degrader of PARP1

A DNA/Upconversion Nanoparticle Complex Enables Controlled Co‐Delivery of CRISPR‐Cas9 and Photodynamic Agents for Synergistic Cancer Therapy

Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-targeting PROTAC Small Molecule

A Photosensitizer-Loaded Polydopamine Nanomedicine Agent for Synergistic Photodynamic and Photothermal Therapy

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

A nuclear targeted dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS.